N,O-Dimethylhydroxylamine hydrochloride | CAS:6638-79-5

We serve N,O-Dimethylhydroxylamine hydrochloride CAS:6638-79-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
N,O-Dimethylhydroxylamine hydrochloride

Chemical Name:N,O-Dimethylhydroxylamine hydrochloride
CAS.NO:6638-79-5
Synonyms:DMHH; n-methoxy-methanaminhydrochloride
O,N-DIMETHYLHYDROXYLAMINE HCL
N,O-DIMETHYLHYDROXYLAMINE HCL
Molecular Formula:C2H8ClNO
Molecular Weight:97.54400
 
Physical and Chemical Properties:
Melting point:112-115ºC
 
Specification:
Appearance:White to light yellow crystalline powder
Purity:≥98.0%
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Applicationd in amide coupling reactions to form Weinreb amides for use in the Weinreb ketone synthesis. As for the synthesis of organic intermediates, pharmaceutical, pesticide.



Contact us for information like N,O-Dimethylhydroxylamine hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N,O-DIMETHYLHYDROXYLAMINE HCL physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N,O-DIMETHYLHYDROXYLAMINE HCL Use and application,O,N-DIMETHYLHYDROXYLAMINE HCL technical grade,usp/ep/jp grade.


Related News: Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.Trimethoxy(methyl)silane manufacturer But several border points remain open, and many medical workers fear that Hong Kong’s well-regarded health care system will be overwhelmed.1-Ethyl-4-piperidone supplier Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.4-Chlorophenylacetonitrile vendor Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.Three more patients have been confirmed infected with coronavirus in South Korea, bringing the country’s total to 15, the South Korean Centers for Disease Control and Prevention (KCDC) announced in a press release.